Rockefeller Capital Management
AIMT

Rockefeller Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Rockefeller Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,754
Closed -$60K – 3097
2020
Q3 		$60K Sell
1,754
-512
-23% -$10.9K ﹤0.01% 1451
2020
Q2 		$38K Buy
2,266
+979
+76% +$16.6K ﹤0.01% 1488
2020
Q1 		$19K Buy
1,287
+1,285
+64,250% +$32.8K ﹤0.01% 1542
2019
Q4 		$0 Buy
+2
New +$56 ﹤0.01% 2273

Rockefeller Capital Management's AIMT Position: Q4 2020 in Review

Rockefeller Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 1,754 shares — an estimated $60K sold.

Rockefeller Capital Management first reported a position in AIMT in Q4 2019 and held it in 4 quarters. The position peaked at $60K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Rockefeller Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Rockefeller Capital Management sold 1,754 Aimmune Therapeutics shares in Q4 2020, an estimated $60K.
  • Rockefeller Capital Management first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 4 quarters.
  • Rockefeller Capital Management's Aimmune Therapeutics position peaked at $60K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Rockefeller Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.